维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

1篇 您的检索式：作者名="Nicolas A.Fraunhoffer"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Limitation and challenges in using pancreatic cancer-derived organoids as a preclinical tool显示文摘Dear Editor,Pancreatic ductal adenocarcinoma(PDAC)is a dismal disease with a fast evolution and unpredictable treatment response.Nowadays,FOLFIRINOX[1]and gemcitabine[2]are the preferred treatments with a response rate of 33%and 11%,respectively.This poor patient response has been associated with an inefficient/non-personalized treatment allocation.Consequently,developing a rapid and efficient preclinical tool to test tumor drug sensitivity for each patient is hugely needed.Biopsy patient-derived organoid(PDO)appears to be a promising tool for developing individualized treatments for patients with PDAC.Several PDO-based platforms are in development worldwide as a guide to optimize therapy by directing tailored treatments.A critical point to consider PDO as promising is that it must represent the great clinical heterogeneity of PDAC as much as possible.Moreover,PDO has displayed histological features that mimic the PDAC phenotype.These characteristics make PDO an interesting option to obtaining reliable chemo-response profiles at a reasonable timeframe for most PDAC patients.	Nicolas A.Fraunhoffer Analía Meilerman Abuelafia Nelson Dusetti Juan Iovanna	2022	Cancer Communications2022，42，10：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费